Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany
The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study is to provide reliable regression-based estimates of costs associated with different type 2 diabetes complications. RESEARCH DESIGN AND METHODS: We used nationwide statutory health insurance (SHI) data from 316,220 patients with type 2 diabetes. Costs for inpatient and outpatient care, pharmaceuticals, rehabilitation, and nonmedical aids and appliances were assessed in the years 2013–2015. Quarterly observations are available for each year. We estimated costs (in 2015 euro) for complications using a generalized estimating equations model with a normal distribution adjusted for age, sex, occurrence of different complications, and history of complications at baseline, 2012. Two- and threefold interactions were included in an extended model. RESULTS: The base case model estimated total costs in the quarter of event for the example of a 60- to 69-year-old man as follows: diabetic foot €1,293, amputation €14,284, retinopathy €671, blindness €2,933, nephropathy €3,353, end-stage renal disease (ESRD) €22,691, nonfatal stroke €9,769, fatal stroke €11,176, nonfatal myocardial infarction (MI)/cardiac arrest (CA) €8,035, fatal MI/CA €8,700, nonfatal ischemic heart disease (IHD) €6,548, fatal IHD €20,942, chronic heart failure €3,912, and angina pectoris €2,695. In the subsequent quarters, costs ranged from €681 for retinopathy to €6,130 for ESRD. CONCLUSIONS: Type 2 diabetes complications have a significant impact on total health care costs in the SHI system, not only in the quarter of event but also in subsequent years. Men and women from different age-groups differ in their costs for complications. Our comprehensive estimates may support the parametrization of diabetes models and help clinicians and policy makers to quantify the economic burden of diabetes complications in the context of new prevention and treatment programs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nine articles [50–58] considered costs associated with DR and its associated complications (i.e. DMO).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [51]
In the citing paper
“Costs pertaining to DR and its complications (including DMO) were combined in three studies [50, 51, 53], whereas costs in patients affected by both DR and DMO simultaneously were reported in two studies [52, 53] (Supplementary Tables 3 and 8).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [51]
In the citing paper
“Of note, eight studies [47–53, 59] did not distinguish between costs of different conditions, further hindering the interpretation.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [51]
Citations
Cites
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives
Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.183 · Cited by 2,227 · cited 1×
“The shift in risk factors aswell as demographics is contributing to the increasing prevalence worldwide, especially among younger age-groups (3).”
BackgroundThe Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“which is further driven by the occurrence ofmultiple heterogeneous complications (4).”
BackgroundReview of statistical methods for analysing healthcare resources and costs
Mihaylova, B., Briggs, A., O'Hagan, A., & Thompson, S. G. (2011) · Health Economics · doi:10.1002/hec.1653 · Cited by 767 · cited 1×
“In line with literature recommendations, we can assume a near normality of the sample means, as the sample size is sufficiently large and the proportion of zero costs relatively small (,2%) (30).”
BackgroundClarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615
Sex and gender differences in health: Science & Society Series on Sex and Science
Regitz‐Zagrosek, V. (2012) · The EMBO Reports · doi:10.1038/embor.2012.87 · Cited by 572
The CDC Diabetes Cost-effectiveness Group (2002) · JAMA · doi:10.1001/jama.287.19.2542 · Cited by 508
Revealing the cost of Type II diabetes in Europe
Jönsson, B. (2002) · Diabetologia · doi:10.1007/s00125-002-0858-x · Cited by 392
Kassenärztliche Bundesvereinigung
(1985) · Oncology Research and Treatment · doi:10.1159/000215622 · Cited by 306
Research works printed but not linked: 3
- Tamayo, 2016, The prevalence and incidence of diabetes in Germany, Dtsch Arztebl Int, 113, 177
- Chang, 2012, Validating the adapted Diabetes Complications Severity Index in claims data, Am J Manag Care, 18, 721
- Robert Koch Institute, 2014, Diabetes Mellitus: Fact Sheet for GEDA 2012: Results of the “Health in Germany Study 2012.”
Cited by
Items 101–140 of 140
Ponomarenko, S. (2019) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909.2019.12.3.178-190 · Cited by 1
“2 trillion in 2030 and will have a heavy impact on the economies of LND countries [9,18-19].”
Debus, E. S., & Grundmann, R. T. (2018) · Evidenzbasierte Chirurgie · doi:10.1007/978-3-662-57709-7_17 · Cited by 1
The Global Threat of Non-Communicable Diseases – Cost and Drivers for Diabetes Type 2 in Germany
Scherdjow, A., Kiefer, S., Lüske, J., & Althaus, A. E. (2022) · Gesundheitsökonomie & Qualitätsmanagement · doi:10.1055/a-1823-2620 · Cited by 1
Gruessner, R. W. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_79 · Cited by 1
Eckhard, M., & Engels, G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01104-6 · Cited by 1
Vetter, V. M., Spieker, J., Sommerer, Y., Buchmann, N., Kalies, C. H., Regitz‐Zagrosek, V., Bertram, L., & Demuth, I. (2022) · medRxiv · doi:10.1101/2022.06.28.22276991 · Cited by 1
“A substantial part of these costs was attributed to diabetic complications [2, 7-10].”
BackgroundLiu, J., Ren, R., Li, Y., Bai, J., Yao, Z., Ye, X., Zhang, R., Wang, L., & Wang, D. (2025) · Research Square · doi:10.21203/rs.3.rs-6676665/v1 · Cited by 2
Mohebbi, D., Vomhof, M., Montalbo, J., Winkels, A. K., Gontscharuk, V., Chernyak, N., Dintsios, C., Kairies‐Schwarz, N., Stark, R., Emmert-Fees, K. M. F., et al. (2026) · medRxiv · doi:10.64898/2026.05.22.26353768 · Cited by 1
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“All four studies had an observational study design and were conducted in Germany [51, 53], Norway [50] and Sweden [52].”
InfluentialKomorbiditäten bei Typ‑2-Diabetes
Weber, D., & Kaltheuner, M. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0405-0
Wundversorgung beim diabetischen Fußsyndrom
Dörr, S., Stilinovic, K., & Lobmann, R. (2018) · PRO CARE · doi:10.1007/s00735-018-0937-y
Editorial: Diabetes surveillance in Germany – status and perspectives
Scheidt‐Nave, C., & Icks, A. (2019) · Publication server of the Robert Koch Institute (Robert Kock Institute) · doi:10.25646/5985 · Cited by 1
Update: Wundversorgung beim diabetischen Fußsyndrom
Dörr, S., Stilinovic, K., & Lobmann, R. (2018) · Pflegezeitschrift · doi:10.1007/s41906-018-0491-z
Li, R., Zheng, Z., Li, W., Ying, J., Song, Y., Zhang, Y., & Zhang, M.-N. (2019) · Research Square · doi:10.21203/rs.2.9417/v1
“Studies have shown that hospitalization costs are closely related to age, gender and complication type [16].”
BackgroundFritsche, A., Icks, A., Schulze, M. B., & Szendrödi, J. (2021) · Diabetes aktuell · doi:10.1055/a-1397-3379
To study association of Neutrophil- Lymphocyte ratio with vascular complications in Type-2 Diabetes
Gowda, S. T. A., Kusumakar, S. H., Raveendra, K. R., & Rohith, M. G. (2021) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v12i8.36161
Zamani, M., Rahmanian, V., Rezaei, S., Khubfekr, H., & Namdar, A. (2021) · Research Square · doi:10.21203/rs.3.rs-250793/v1
Risikofaktoren für Amputationen bei Diabetes mellitus Typ 1
Seibold, J. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00838-5
Diabetic complications impact healthcare costs in T2DM
(2018) · PharmacoEconomics & Outcomes News · doi:10.1007/s40274-018-4686-8
(2018) · British Journal of Hospital Medicine · doi:10.12968/hmed.2018.79.3.128
Application Value of Neutrophil to Lymphocyte Ratio in Diabetic Retinopathy
易, 静. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125548
Privacy-preserving personal data analysis
Sun, C. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20221114cs
Dissemond, J., & Lobmann, R. (2022) · Aktuelle Dermatologie · doi:10.1055/a-1904-3302
Auswirkungen von Diabetes-Komplikationen
Smokovski, I. (2023) · Springer eBooks · doi:10.1007/978-3-031-27793-1_3
TYPE 2 DIABETES AND BONE HEALTH: an epidemiological approach
Viggers, R. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau561779793 · Cited by 1
Marrugo, B. (2022) · International Journal of Nuclear Medicine & Radioactive Substances · doi:10.23880/ijnmrs-16000149
Morbach, S., Hochlenert, D., & Eckhard, M. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01140-2
Görtz, H., & Eckhard, M. (2024) · Gefässchirurgie · doi:10.1007/s00772-024-01087-8
Stephan, A., Hanselmann, M., Bajramovic, M., Schoßer, S., & Laxy, M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4781312
Self-citationOutcomes of PCI of all comers: the experience of a Kuwaiti independent healthcare institution
Mudawi, T. O., Alenezi, W., Amin, A., Besada, D., Aly, A., Fathi, A., Khdair, D. A., & Alanbaei, M. (2024) · British Journal of Cardiology · doi:10.5837/bjc.2024.016
Economic and Financial Issues in Pancreas Transplantation
(2024) · Archives of Health Science · doi:10.31829/2641-7456/ahs2024-8(1)-007
Fan, M., Stephan, A., Hanselmann, M., Lueg, A., & Laxy, M. (2025) · Applied Health Economics and Health Policy · doi:10.1007/s40258-025-00978-5
Self-citationStegbauer, C., Falivena, C., Moreno, A., Hentschel, A., Rosenmöller, M., Heise, T., Szecsenyi, J., & Schliess, F. (2020) · Figshare · doi:10.6084/m9.figshare.13245818
Wu, Y., Xiong, T., Tan, X., & Chen, L. (2024) · Figshare · doi:10.6084/m9.figshare.26551939
Sund, R., Peltonen, T. O., Lehtimäki, A.-V., & Martikainen, J. (2022) · Figshare · doi:10.6084/m9.figshare.19568707
Chen, G., Che, L., Lai, M., Wei, T., Chen, C., Zhu, P., & 冉建民 (2024) · Figshare · doi:10.6084/m9.figshare.25801045
Chao, C.-T., Lee, S.-Y., Wang, J., Chien, K., & Hung, K. (2021) · Figshare · doi:10.6084/m9.figshare.14479946
de Albuquerque, R. P., Walraven, R. B., Cruz, J. A. S. D., & Sardenberg, R. A. D. S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02287-x
“Younger patients and men exhibited greater numerical reductions in weight and BMI, findings that are consistent with previous observational studies suggesting that demographic and behavioral factors influence response to diabetes management interventions [12].”
Zhang, M., Du, Y. U. A. N., Li, A., Lau, E. S. H., Wu, H., Kong, A. P. S., Luk, A. O. Y., Ronald, C. W., Chun Kwan, O., Lim, L., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113433
Hille, H., Schramm, W., & Bounekkar, A. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00801-5
“Cost data for Germany, including state and medication cost, were gathered from a reliable cost of illness study by Kähm et al. [12].”
Metadata
- Authors
- Kähm, K., Laxy, M., Schneider, U., Rogowski, W. H., Lhachimi, S. K., & Holle, R.
- Affiliations
- Helmholtz Munich (DE)
- Techniker Krankenkasse (Germany) (DE)
- University of Bremen (DE)
- Corresponding author
- Kähm, Katharina
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-01-18
- Volume
- 41
- Issue
- 5
- Pages
- 971-978
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2789481148
- Cited by
- 141
- References
- 33
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 12 · 2023: 19 · 2022: 24 · 2021: 20 · 2020: 29 · 2019: 13 · 2018: 9
- FWCI
- 27.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Keywords
- type 2 diabetes, diabetes complications, health care costs, economic burden of disease, diabetic foot, amputation, diabetic retinopathy, blindness, diabetic nephropathy, end-stage renal disease, stroke, myocardial infarction, ischemic heart disease, chronic heart failure, angina pectoris, sex differences, age differences, statutory health insurance, Germany
- MeSH terms
- Aged, Ambulatory Care, Amputation, Surgical, Diabetes Mellitus, Type 2, Female, Germany, Heart Failure, Humans, Male, Middle Aged, Myocardial Infarction, Health Care Costs, Diabetic Foot, Stroke, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.